Thromb Haemost 1986; 55(02): 259-262
DOI: 10.1055/s-0038-1661532
Original Article
Schattauer GmbH Stuttgart

The Systemic Fibrinolytic Effect of BRL 26921 During the Treatment of Acute Peripheral Arterial Occlusions

J J Earnshaw
1   The Department of Vascular Surgery, University Hospital, Nottingham, UK
,
J C Westby
2   The Department of Haematology, University Hospital, Nottingham, UK
,
G S Makin
1   The Department of Vascular Surgery, University Hospital, Nottingham, UK
,
B R Hopkinson
1   The Department of Vascular Surgery, University Hospital, Nottingham, UK
› Author Affiliations
Further Information

Publication History

Received 29 October 1985

Accepted 18 February 1986

Publication Date:
18 July 2018 (online)

Summary

BRL 26921 is a new acylated streptokinase-plasminogen complex which may have a more specific local thrombolytic effect than streptokinase or urokinase. 34 patients with acute peripheral arterial occlusions were given eight hourly bolus injections of 5 mg BRL 26921 for up to 72 h. Systemic fibrinolysis was observed in all patients yet in only 24% was the occluding thrombus lysed. 44% of the patients had haemorrhagic complications and 24% suffered further thrombotic events during or soon after treatment. There was no correlation between the degree of systemic fibrinolysis produced and dissolution of the thrombi. The degree of systemic fibrinolysis did not affect the complication rate. There is no evidence from this study that BRL 26921 has a specific local thrombolytic effect.

 
  • References

  • 1 Amery A, Deloof W, Vermylen J, Verstraete M. Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. B M J 1970; 4: 639-644
  • 2 Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low dose streptokinase. Radiology 1974; 111: 31-37
  • 3 Hess H, Ingrisch H, Mietaschk A, Rath H. Local low dose thrombolytic therapy for peripheral arterial occlusions. N E J Med 1982; 307 (26) 1627-1630
  • 4 Mori KW, Bookstein JJ, Heeney DJ, Bardin JA, Donnelly KJ, Rhodes GA, Dillay RB, Warmath MA, Bernstein EF. Selective streptokinase infusion: clinical and laboratory correlates. Radiology 1983; 148: 677-682
  • 5 Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl enzymes: a new approach to thrombolytic therapy. Nature 1981; 290 5806 505-508
  • 6 Fears R, Green J, Smith RAG, Walker P. Induction of a sustained fibrinolytic response by BRL 26921 in vitro. Thromb Res 1985; 38: 251-260
  • 7 Smith RAG, Dupe RJ, English PD, Green J. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemostas 1982; 47: 269-274
  • 8 Dupe RJ, Green J, Smith RAG. Acylated derivatives of strepto-kinase-plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. Thromb Haemostas 1985; 53: 56-59
  • 9 Marder VJ, Francis CW, Norry EC. Dose-ranging study of acylated streptokinase-plasminogen complex (BRL 26921). Thromb Haemostas 1980; 50: 321 (Abstr)
  • 10 Prowse CV, Hornsey V, Ruckley CV, Boulton FE. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers. Thromb Haemostas 1982; 47: 132-135
  • 11 Staniforth DH, Smith RAG, Hibbs M. Streptokinase and anisoy-lated streptokinase-plasminogen complex. Their action on heamos-tasis in human volunteers. Eur J Clin Pharm 1983; 24: 751-756
  • 12 Walker ID, Davidson JF, Rae AP, Hutton I, Laurie TD V. Acylated streptokinase-plasminogen complex in patients with acute myocardial infarction. Thromb Haemostas 1984; 51: 204-206
  • 13 Hoffman J JM L, Van Rey F JW, Bonnier J JR M. Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction. Thromb Res 1985; 37: 567-572
  • 14 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasma inhibitor in human blood by means of a specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
  • 15 Soria J, Soria C, Samama M. Dosage du plasminogene a l’aide d’un substrat chromogene tripeptidique. Path Biol 1976; 24: 725-729
  • 16 Clauss A von. Gerinnungsphysiologische Schnellmethode zur Be-stimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
  • 17 Buckell M. The effect of citrate on euglobulin methods of measuring fibrinolytic activity. J Clin Path 1958; 11: 403-405
  • 18 Working party of the International Vascular Symposium. The definition of critical ischaemia of a limb. Br J Surg 1982 69. s2
  • 19 Graor RA, Risius B, Young JR, Geisinger MA, Zelch MG, Smith J AM, Ruschhaupt WF. Low dose streptokinase for selective thrombolysis: systemic effects and complications. Radiology 1984; 152: 35-39
  • 20 Hurley JJ, Burrell BJ, Auer AI, Woods JJ, Bunnington HB, Hershey FB. Surgical implications of fibrinolytic therapy. Am J Surg 1984; 148: 830-835
  • 21 Persson AV, Robichaux WT, Jaxheimer EC, Dipronio EM. Burst therapy: a method of administering fibrinolytic agents. Am J Surg 1984; 147: 531-536
  • 22 Becker GJ, Rabe FE, Hogan RD, Evan EP, Franklin TD, Holden RW, Bang NU, Dilley RS, Bendick PJ, Klatte EC. Thrombolytic agents: effects of local infusions on microvascular pathology and macrovascular ultrastructure. Radiology 1983; 148: 403-406
  • 23 Conrad J, Samama M. Laboratory control of streptokinase therapy. Thromb Haemostas 1973; (Suppl. 56) 191-198